<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>nab-paclitaxel &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/nab-paclitaxel/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 06 Oct 2026 05:24:39 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.2</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>nab-paclitaxel &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>A gentler chemo schedule may match standard care in advanced pancreatic cancer</title>
		<link>https://bioengineer.org/a-gentler-chemo-schedule-may-match-standard-care-in-advanced-pancreatic-cancer/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 06 Oct 2026 05:24:39 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[biweekly dosing]]></category>
		<category><![CDATA[chemotherapy toxicity]]></category>
		<category><![CDATA[Dose optimization]]></category>
		<category><![CDATA[Gemcitabine]]></category>
		<category><![CDATA[metastatic pancreatic ductal adenocarcinoma]]></category>
		<category><![CDATA[nab-paclitaxel]]></category>
		<category><![CDATA[neutropenia]]></category>
		<category><![CDATA[overall survival]]></category>
		<category><![CDATA[pancreatic cancer]]></category>
		<category><![CDATA[peripheral neuropathy]]></category>
		<category><![CDATA[Real-world evidence]]></category>
		<category><![CDATA[systematic review]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=403646</guid>

					<description><![CDATA[A systematic review of five real-world studies finds that a biweekly gemcitabine and nab-paclitaxel schedule matches standard survival outcomes in advanced pancreatic cancer while reducing severe neutropenia and neuropathy.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">403646</post-id>	</item>
	</channel>
</rss>
